Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

Individualised therapy in advanced urothelial cancer: Prime time?

Chemotherapy, immunotherapy or combinations: What is the best option in the face of new evidence?

Date

16 Oct 2020

Session

Individualised therapy in advanced urothelial cancer: Prime time?

Topics

Cytotoxic Therapy;  Immunotherapy

Tumour Site

Urothelial Cancer

Presenters

Alison Birtle

Authors

A. Birtle

Author affiliations

  • Royal Preston Hospital-Lancashire Teaching Hospitals NHS Foundation Trust, PR2 9HT - Preston/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

What to do if immunotherapy fails?

Presenter: Aristotelis Bamias

Session: Individualised therapy in advanced urothelial cancer: Prime time?

Resources:

Slides

Webcast

Q&A and live discussion

Presenter: Alison Birtle

Session: Individualised therapy in advanced urothelial cancer: Prime time?

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.